

# YTD 2024 HIGHLIGHTS



“Since the launch of our strategy in 2020, we have enjoyed uninterrupted growth. This quarter was no exception and was accompanied by further progress in the pipeline”


**David Loew**  
Chief Executive Officer

## FY 2024 GUIDANCE INCREASED

Total sales growth greater than **8.0%** (at CER)

Core operating margin Greater than **31.0%** of total sales

## TOTAL SALES




■ Oncology  
■ Rare Disease  
■ Neuroscience

## GEOGRAPHIC BREAKDOWN

### YTD 2024 TOTAL SALES BY REGION

**34%** North America    **39%** Europe    **27%** Rest of World



## ONCOLOGY +6%



## RARE DISEASE +71%



## NEUROSCIENCE +12%



## RECENT PIPELINE DEVELOPMENTS

- E.U. regulatory approval - Iqirvo: 2L PBC
- E.U. regulatory approval - Kayfanda: ALGS
- E.U. regulatory submission - Cabometyx: NETs

## OTHER

- Sale of rare pediatric disease Priority Review Voucher
- Divestment of Increlex<sup>®</sup> (mecasermin injection)

For further information on Ipsen's YTD 2024 sales update and definitions of financial indicators, please refer to the press release at:



[www.ipsen.com/investors](http://www.ipsen.com/investors)

**Nicolas Bogler**

Senior Manager, Investor Relations  
+33 6 52 19 98 92  
nicolas.bogler@ipsen.com

2L: second line; PBC: primary biliary cholangitis; ALGS: Alagille syndrome; NETs: neuroendocrine tumours.

All growth rates are at constant exchange rates (CER).